Germline mutations in driver oncogenes and inherited lung cancer risk independent of smoking history

Journal of the National Cancer Institute

Volumn 106, Issue 1, 2014, Pages

  Oxnard, Geoffrey R ^a   Nguyen, Kim Son H ^b   Costa, Daniel B ^c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b STANFORD UNIVERSITY   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN;

ALLELE; AMINO ACID SUBSTITUTION; CANCER PATIENT; CANCER RISK; EDITORIAL; FAMILY HISTORY; GENE EXPRESSION; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENOTYPE; GERM LINE; GERMLINE MUTATION; HUMAN; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; ONCOGENE; POINT MUTATION; PRIORITY JOURNAL; PROTO ONCOGENE; RISK FACTOR; SMOKING; ADENOCARCINOMA; FEMALE; GENETICS; LUNG TUMOR; MALE; MUTATION; NOTE;

ADENOCARCINOMA; FEMALE; GERM-LINE MUTATION; HUMANS; LUNG NEOPLASMS; MALE; RECEPTOR, ERBB-2;

EID: 84892662743     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djt361     Document Type: Editorial

References (23)

1. Brennan P, Hainaut P, Boffetta P. Genetics of lung-cancer susceptibility. Lancet Oncol. 2011;12(4):399-408.
2. Thorgeirsson TE, Geller F, Sulem P, et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature. 2008;452(7187):638-642.
3. Foulkes WD. Inherited susceptibility to common cancers. N Engl J Med. 2008;359(20):2143-2153.
4. Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers-a different disease. Nat Rev Cancer. 2007;7(10):778-790.
5. Oxnard GR, Binder A, Janne PA. New targetable 1 oncogenes in nonsmall-cell lung cancer. J Clin Oncol. 2013;31(8):1097-1104.
6. Costa DB. Identification of somatic genomic alterations in circulating tumors cells: another step forward in non-small-cell lung cancer? J Clin Oncol. 2013;31(18):2236-2239.
7. Li Y, Sheu CC, Ye Y, et al. Genetic variants and risk of lung cancer in never smokers: a genome-wide association study. Lancet Oncol. 2010;11(4):321-330.
8. Lan Q, Hsiung CA, Matsuo K, et al. Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia. Nat Genet. 2012;44(12):1330-1335.
9. Gaughan EM, Cryer SK, Yeap BY, Jackman DM, Costa DB. Family history of lung cancer in never smokers with non-small-cell lung cancer and its association with tumors harboring EGFR mutations. Lung Cancer. 2013;79(3):193-197.
10. Bell DW, Gore I, Okimoto RA, et al. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat Genet. 2005;37(12):1315-1316.
11. Oxnard GR, Miller VA, Robson ME, et al. Screening for germline EGFR T790M mutations through lung cancer genotyping. J Thorac Oncol. 2012;7(6):1049-1052.
12. Vikis H, Sato M, James M, et al. EGFR-T790M is a rare lung cancer susceptibility allele with enhanced kinase activity. Cancer Res. 2007;67(10):4665-4670.
13. Girard N, Lou E, Azzoli CG, et al. Analysis of genetic variants in never-smokers with lung cancer facilitated by an Internet-based blood collection protocol: a preliminary report. Clin Cancer Res. 2010;16(2):755-763.
14. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005;352(8):786-792.
15. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005;2(3):e73.
16. Nguyen KS, Kobayashi S, Costa DB. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer. 2009;10(4):281-289.
17. Ikeda K, Nomori H, Mori T, Sasaki J, Kobayashi T. Novel germline mutation: EGFR V843I in patient with multiple lung adenocarcinomas and family members with lung cancer. Ann Thorac Surg. 2008;85(4):1430-1432.
18. Yamamoto H, Higasa K, Sakaguch M, et al. Novel germ-line mutation in the transmembrane domain of HER2 in familial lung adenocarcinomas. JNCI J Natl Cancer Inst (2014) 106 (1): djt338 doi:10.1093/jnci/djt338
19. Shigematsu H, Takahashi T, Nomura M, et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res. 2005;65(5):1642-1646.
20. Perera SA, Li D, Shimamura T, et al. HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy. Proc Natl Acad Sci USA. 2009;106(2):474-479.
21. Serra V, Vivancos A, Puente XS, et al. Clinical response to a lapatinib-based therapy for a Li-Fraumeni syndrome patient with a novel HER2V659E mutation. Cancer Discov. 2013;3(11):1238-1244.
22. Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol. 2013;8(7):823-859.
23. Oxnard GR, Heng JC, Rainville IR, et al. Investigating hereditary risk from T790M (inherit): a prospective multicentered study of risk associated with germ-line EGFR T790M. J Clin Oncol. 2013;31(suppl):abstract TPS1606.